John Leonard, Intellia Therapeutics CEO
November 18, 2024 04:09 AM ESTUpdated 06:21 AM
R&D
Cell/Gene Tx

In­tel­lia touts first clin­i­cal out­comes on CRISPR-based AT­TR amy­loi­do­sis as­set

Lei Lei Wu

News Reporter

In one of the most close­ly-watched are­nas in biotech, In­tel­lia says its gene edit­ing treat­ment for a heart mus­cle dis­ease can sta­bi­lize or im­prove out­comes …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Scot­tish biotech de­buts with ‘Tro­jan horse’ plat­form for can­cer

Ei­sai ter­mi­nates Phase 3 tri­al of Dravet drug, cit­ing re­cruit­ment chal­lenges

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

Ex­clu­sive: Athena Coun­tou­ri­o­tis' Aven­zo taps Shang­hai biotech for ADC, adds new funds

Cy­bin says its psy­che­del­ic drug can sus­tain re­mis­sion in de­pres­sion pa­tients

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times